DNA Methylation and TMPRSS2-ERG Fusion Status in Patients with Prostate Cancer from The Republic of North Macedonia

Sample	Age	PSA	GMa¹	GMin²	GS³	TMPRSS2–ERG Real-Time PCR	Sample	Age	PSA	GMa¹	GMin²	GS³	TMPRSS2–ERG Real-Time PCR
Ca P - 1	62	9,7	3	3	6	Negative, type	Ca P – 45	73	14	3	3	6	Negative, type
Ca P – 2	63	32	4	4	8	Negative, type	Ca P – 46	63	100	4	4	8	Negative, type
Ca P – 3	74	16,5	4	5	9	Negative, type	Ca P – 47	77	7,4	3	3	6	Negative, type
Ca P – 4	74	84	3	4	7	Negative, type	Ca P – 48	76	65	4	3	7	Positive, type *
Ca P – 5	64	8,28	3	3	6	Negative, type	Ca P – 49	60	44	3	4	7	Positive, type *
Ca P – 6	71	7,38	3	4	7	Positive, type *	Ca P – 50	80	45,3	3	4	7	Positive, type *
Ca P – 7	78	17	3	4	7	Negative, type	Ca P – 51	64	12	3	3	6	Negative, type
Ca P – 8	64	45	4	4	8	Positive, type *	Ca P – 52	74	10,2	4	3	7	Negative, type
Ca P - 9	72	20,1	3	3	6	Negative, type	Ca P – 53	85	58	3	3	6	Negative, type
Ca P – 10	64	4,33	3	3	6	Positive, type *	Ca P – 54	75	25	3	4	7	Positive, type *
Ca P - 11	59	9,15	4	3	7	Positive, type *	Ca P – 55	67	20,5	4	3	7	Negative, type
Ca P - 12	70	8,53	3	3	6	Negative, type	Ca P – 56	72	9,28	3	3	6	Positive, type *
Ca P - 13	74	14	4	3	7	Negative, type	Ca P – 57	64	37	3	4	7	Positive, type *
Ca P - 14	61	4,5	3	3	6	Negative, type	Ca P – 58	68	13,3	3	3	6	Negative, type
Ca P - 15	55	63,5	4	4	8	Negative, type	Ca P – 59	61	6,1	3	5	8	Negative, type
Ca P - 16	85	24	3	3	6	Positive, type *	Ca P – 60	69	8,2	3	3	6	Negative, type
Ca P - 17	70	9,4	3	3	6	Positive, type *	Ca P – 61	71	14,5	4	4	8	Negative, type
Ca P - 18	78	15,5	5	3	8	Positive, type *	Ca P – 62	77	68,9	4	3	7	Negative, type
Ca P - 19	69	18	3	3	6	Positive, type *	Ca P – 63	77	25	4	3	7	Positive, type *
Ca P - 20	71	9,7	3	4	7	Negative, type	Ca P – 64	70	12	3	4	7	Negative, type
Ca P - 21	67	18	3	3	6	Negative, type	Ca P – 65	65	42,1	4	4	8	Positive, type *
Ca P – 22	74	70	4	4	8	Negative, type	Ca P – 66	62	26,2	3	3	6	Positive, type *
Ca P – 23	69	22,3	4	4	8	Negative, type	Ca P – 67	70	10,6	3	3	6	Negative, type
Ca P - 24	68	9,44	4	3	7	Negative, type	Ca P – 68	78	102	3	4	7	Negative, type
Ca P - 25	70	45,8	4	5	9	Negative, type	Ca P – 69	74	6,1	3	4	7	Positive, type *
Ca P – 26	67	12,7	3	3	6	Negative, type	Ca P – 70	58	10,3	3	3	6	Positive, type *
Ca P - 27	62	24	4	3	7	Negative, type	Ca P –71	65	5,8	3	4	7	Positive, type *
Ca P - 28	64	94	4	4	8	Positive, type *	Ca P – 72	70	11,7	3	4	7	Negative, type
Ca P – 29	50	12,2	3	3	6	Positive, type *	Ca P – 73	70	14	3	3	6	Positive, type *
Ca P – 30	66	6,1	3	3	6	Negative, type	Ca P –74	70	9,72	4	4	8	Positive, type *
Ca P - 31	53	70	3	4	7	Positive, type *	Ca P – 75	72	14,3	4	3	7	Negative, type
Ca P - 32	69	116	4	5	9	Positive, type *	Ca P - 76	77	20	4	3	7	Positive, type *
Ca P - 33	71	7	4	3	7	Negative, type	Ca P - 77	81	5,42	3	3	6	Negative, type
Ca P - 34	63	6,2	3	3	6	Negative, type	Ca P – 78	78	38	4	3	7	Positive, type *
Ca P – 35	64	148	4	3	7	Negative, type	Ca P – 79	75	10,4	3	4	7	Positive, type *
Ca P – 36	77	150	4	3	7	Negative, type	Ca P - 80	68	11	3	3	6	Negative, type
Ca P – 37	65	4,7	3	4	7	Negative, type	Ca P - 81	69	23	4	4	8	Positive, type *
Ca P – 38	61	7,1	3	4	7	Negative, type	Ca P - 82	70	7,8	3	3	6	Positive, type *
Ca P – 39	80	90	5	4	9	Negative, type	Ca P - 83	55	11,6	3	3	6	Negative, type
Ca P – 40	62	7,62	5	3	8	Negative, type	Ca P – 84	75	11	3	3	6	Positive, type *
Ca P – 41	72	8	3	4	7	Negative, type	Ca P – 85	62	7,5	3	3	6	Negative, type
Ca P – 42	76	21,3	3	3	6	Negative, type	Ca P – 86	70	90	3	4	7	Negative, type
Ca P – 43	77	8,5	4	5	9	Negative, type	Ca P – 87	54	8,5	3	3	6	Negative, type
Ca P – 44	59	152	4	4	8	Negative, type	Ca P – 88	72	43	3	5	8	Negative, type

1 GMa - Gleason Major

2 GMin - Gleason Major

3 GSMa - Gleason Score

Table 2.

Qualitative genome-wide DNA methylation among patients with prostate cancer and gene correlation TMPRSS2 – ERG RT-PCR, age, PSA and Gleason Score

DNA methylation Genes	N (%)	Cohen’s kappa (κ)¹	Correlation
DNA methylation Genes	N (%)	Cohen’s kappa (κ)¹	Age	PSA	Gleason Score
CASP8-3	22 (25,00%)	κ = 0,158 [95% CI (0,049 – 0,360)]; p = 0,125	r (88)=0,124; p=0,251	r (88)=0,199; p=0,062	r (88)=0,369; p=0,0003*
RARB-1	39 (44,32%)	κ = 0,179 [95% CI (0,017 – 0,377)]; p = 0,089	r (88)=0,085; p=0,432	r (88)=0,335; p=0,001*	r (88)=0,399; p=0,0001*
RASSF1-1	56 (63,64%)	κ = 0,154 [95% CI (0,021 – 0,331)]; p = 0,094	r (88)=0,251; p=0,018*	r (88)=0,171; p=0,111	r (88)=0,274; p=0,009*
APC-2	37 (42,04%)	κ = 0,121 [95% CI (0,092 – 0,318)]; p = 0,253	r (88)=0,148; p=0,167	r (88)=0,364; p=0,004*	r (88)=0,364; p=0,0004*
ESR1-1	8 (9,09%)	κ = 0,112 [95% CI (−0,232 – 0,022)]; p = 0,141	-	-	-
CD44-1	11 (12,50%)	κ = 0,171 [95% CI (0,000 – 0,357)]; p = 0,044*	r (88)=0,205; p=0,056	r (88)=0,064; p=0,552	r (88)=0,122; p=0,259
GSTP1-1	47 (53,41%)	κ = 0,219 [95% CI (0,038 – 0,414)]; p = 0,029*	r (88)=0,181; p=0,094	r (88)=0,274; p=0,009*	r (88)=0,339; p=0,001*
CADM1-1	1 (1,14%)	κ = 0,023 [95% CI (−0,067 – 0,000)]; p = 0,447	-	-	-
CDH13-1	35 (39,77%)	κ = 0,158 [95% CI (−0,045 – 0,363)]; p = 0,138	r (88)=0,154; p=0,152	r (88)=0,284; p=0,007*	r (88)=0,266; p=0,012*
TIMP3-1	2 (2,27%)	κ = 0,045 [95% CI (−0,110 – 0,000)]; p = 0,280	-	-	-

1 Agreement between TMPRSS2 – ERG RT-PCR and selected gene

* significant for p<0,05

References

Authors

Metrics

Articles in this issue

DOI: https://doi.org/10.2478/bjmg-2026-0014 | Journal eISSN: 2199-5761 (formerly 1311-0160) | Journal ISSN: 1311-0160

Journal RSS Feed

Language: English

Page range: 63 - 70

Published on: Oct 14, 2026

Published by: Macedonian Academy of Sciences and Arts

In partnership with: Paradigm Publishing Services

Keywords:

Related subjects:

Basic medical science,

Basic medical science, other

© 2026 A Trifunovski, A Gavrilovska-Brzanov, S Dohchev, J Janculev, D Trajkovski, I Vujicic, G Severova Andreevska, M Ambardjieva, E Dodikj, published by Macedonian Academy of Sciences and Arts
This work is licensed under the Creative Commons Attribution 4.0 License.

Volume 29 (2026): Issue 1 (July 2026)